New Antituberculosis Drugs: From Clinical Trial to Programmatic Use

Treatment of multidrug-resistant tuberculosis (MDR-TB) cases is challenging because it relies on second-line drugs that are less potent and more toxic than those used in the clinical management of drug-susceptible TB. Moreover, treatment outcomes for MDR-TB are generally poor compared to drug sensit...

Descripción completa

Detalles Bibliográficos
Autores principales: Gualano, Gina, Capone, Susanna, Matteelli, Alberto, Palmieri, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927937/
https://www.ncbi.nlm.nih.gov/pubmed/27403268
http://dx.doi.org/10.4081/idr.2016.6569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927937/
https://www.ncbi.nlm.nih.gov/pubmed/27403268
http://dx.doi.org/10.4081/idr.2016.6569

Ejemplares similares